#United States #New York #Class Action #Securities Fraud #Unicycive Therapeutics

Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY)

On September 16, 2025, Levi & Korsinsky, LLP issued a notification to investors regarding a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This action has significant implications for those who held investments in the company between March 29, 2024, and June 27, 2025. The complaint alleges that Unicycive Therapeutics and its representatives made misleading statements about the company’s compliance with FDA manufacturing requirements, falsely portraying the readiness and regulatory potential of a new drug application.

Understanding the Allegations

The class action seeks to recover losses for investors impacted by the alleged securities fraud. Specifically, it points out that Unicycive Therapeutics overstated its capacity to meet the FDA's manufacturing compliance standards and inaccurately represented the prospects of the oxylanthanum carbonate new drug application. As a result, the claims indicate that the public statements made by the company were significantly deceptive throughout the specified time period, affecting investors’ decisions and financial outcomes.

Key Details of the Case

To qualify for inclusion in this class action, investors must have experienced financial losses as a direct result of these claims. The window for submitting requests to be appointed as a lead plaintiff is open until October 14, 2025. It's crucial to understand that participation in the proceedings does not necessitate leading the lawsuit; any class member can share in potential recoveries.

No Financial Burden for Participants

Investors considering joining the class action can take confidence in the fact that participation entails no out-of-pocket costs. Levi & Korsinsky emphasizes that there will be no fees for class members to incur, removing financial barriers for affected investors. The firm operates on the premise that if eligible investors win the case, they may recover compensations without upfront costs.

Why Choose Levi & Korsinsky?

The law firm Levi & Korsinsky boasts a two-decade history in securing favorable outcomes for shareholders, collectively amounting to hundreds of millions of dollars in settlements. This established expertise in navigating complex securities litigation makes them a strong player in fighting for investors' rights. With a dedicated team of over 70 professionals, they have consistently ranked among the top firms in the United States for securities class actions, as indicated by ISS Securities Class Action Services.

Contact Information

For those interested in learning more or participating in the action against Unicycive Therapeutics, contacting Levi & Korsinsky directly is a pivotal step. Investors can reach out to Joseph E. Levi, Esq., or Ed Korsinsky, Esq. at the following address:

Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

This lawsuit represents an important opportunity for affected investors in Unicycive Therapeutics, Inc. to reclaim losses stemming from alleged corporate misrepresentations. Investors are urged to act swiftly to meet the stated deadline and secure their rights under the class action framework.